QUALIblood Announces Strategic Partnership with Diagnostica Stago for the Development and Commercialization of the nAPCsr Kit, a Breakthrough in Thrombosis Risk Assessment

QUALIblood is proud to announce a strategic partnership with Diagnostica Stago to accelerate the development and commercialization of the nAPCsr kit, a pioneering diagnostic tool that promises to redefine thrombosis risk assessment. This collaboration will support the performance and clinical validations of the nAPCsr kit in compliance with the In-Vitro Diagnostic Medical Device Regulation (IVDR), ensuring its robust integration into clinical practice.

Full Press Release (EN)

Communiqué de Presse (FR)

 


Latest news
QUALIblood lab has been successfully granted with the ISO/IEC 17025:2017 accreditation 🏅
QUALIblood SA partners with Immuneed AB to drive innovation and growth in drug development